Abiopharma

🔍 Redmile Group, LLC (Executive)

Company: ADC Therapeutics SA (ADCT)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Sold 196,229 shares of Common Stock at $3.752 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,470,502.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Sold 188,407 shares of Common Stock at $3.752 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,957,305.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 169,265 shares of Common Stock at $3.799 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,301,237.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Sold 162,517 shares of Common Stock at $3.799 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,794,788.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Sold 2,634,506 shares of Common Stock at $3.279 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,666,731.00 | transaction_form_type: 4 | Footnotes: F5, F1
• Sold 2,529,491 shares of Common Stock at $3.279 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,265,297.00 | transaction_form_type: 4 | Footnotes: F5, F2

Footnotes:

• F1: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including RedCo II Master Fund, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
• F2: These securities are directly owned by RedCo II Master Fund, L.P.
• F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.81, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
• F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.83, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
• F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.77, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
• REMARKS: The sales reported herein were effected within a period of less than six months from the purchases of pre-funded warrants to purchase the Issuers' Common Stock reported in the Form 4 filed by the Reporting Persons on October 28, 2025. However, the sales reported herein were effected at a price lower than the previous purchases that were reported in the Form 4 filed on October 28, 2025, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).